Thomas M. Barnes
Chief Executive Officer presso Orna Therapeutics, Inc.
Profilo
Thomas M.
Barnes is currently the Chief Executive Officer & Director at Orna Therapeutics, Inc. and an Executive Partner at MPM BioImpact, Inc. He previously worked as the Director-Genomic Pharmacology at Millennium Pharmaceuticals, Inc., Senior Vice President-Discovery at Ore Pharmaceuticals, Inc., Vice President-Discovery at Sesen Bio, Inc., and Senior VP-Innovative Sciences & eXtellia at Intellia Therapeutics, Inc. Barnes holds a doctorate degree from the University of Cambridge and an undergraduate degree from The University of Sydney.
Posizioni attive di Thomas M. Barnes
Società | Posizione | Inizio |
---|---|---|
Orna Therapeutics, Inc.
Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | Chief Executive Officer | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01/02/2020 |
Precedenti posizioni note di Thomas M. Barnes
Società | Posizione | Fine |
---|---|---|
CARISMA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2013 |
INTELLIA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Ore Pharmaceuticals, Inc.
Ore Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ore Pharmaceuticals, Inc. operates as a drug development company, which developed drug candidates for therapeutic uses. The firm marketed its drug repositioning capabilities to pharmaceutical companies based in North America, Japan and Europe. The company was founded in September 1994 and was headquartered in Wellesley, MA. | Corporate Officer/Principal | - |
Formazione di Thomas M. Barnes
University of Cambridge | Doctorate Degree |
The University of Sydney | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
INTELLIA THERAPEUTICS, INC. | Health Technology |
Aziende private | 5 |
---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Ore Pharmaceuticals, Inc.
Ore Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ore Pharmaceuticals, Inc. operates as a drug development company, which developed drug candidates for therapeutic uses. The firm marketed its drug repositioning capabilities to pharmaceutical companies based in North America, Japan and Europe. The company was founded in September 1994 and was headquartered in Wellesley, MA. | Health Technology |
Sesen Bio, Inc.
Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Orna Therapeutics, Inc.
Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | Health Technology |
- Borsa valori
- Insiders
- Thomas M. Barnes